Dexmedetomidine to reduce vasopressor resistance in refractory septic shock: Protocol for a double-blind randomized controlled pilot trial (ADRESS Pilot study).
Fiche publication
Date publication
août 2022
Journal
Frontiers in medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FOURNEL Isabelle
Tous les auteurs :
Dargent A, Bourredjem A, Argaud L, Levy B, Fournel I, Cransac A, Badie J, Quintin L, Quenot JP
Lien Pubmed
Résumé
Refractory septic shock (RSS) is characterized by high vasopressor requirements, as a consequence of vasopressor resistance, which may be caused or enhanced by sympathetic hyperactivation. Experimental models and clinical trials show a reduction in vasopressor requirements and improved microcirculation compared to conventional sedation. Dexmedetomidine did not reduce mortality in clinical trials, but few septic shock patients were enrolled. This pilot trial aims to evaluate vasopressor re-sensitization with dexmedetomidine and assess the effect size, in order to design a larger trial.
Mots clés
dexmedetomidine, randomized control trial (RCT), refractory septic shock, septic shock (MeSH), vasopressor
Référence
Front Med (Lausanne). 2022 08 9;9:968274